Supporting clinical development and manufacture
Ageing populations, the soaring cost of drug development, and resource constraints impeding the adoption of emergent technologies are just some of the challenges facing the pharmaceutical industry today. The increasing financial burden on the healthcare system as a whole has led to a pressing need for more effective and patient-centric medication. The evolution of pharmaceutical clinical development and manufacture is vital and there are many ways CPI can work with industry to bring about change.
Here at CPI, we are able to support you with the development, optimisation and demonstration of a bespoke manufacturing process that works for the production of your pharmaceutical. Our highly experienced team offer a range of capabilities in both oral solid dose and parenteral dose pharmaceutical manufacture.
Next-generation processing & analytics
We aim to enhance both your small and large molecule API production by utilising our developing cGMP-capable, disruptive processing solutions. Our customers are able to test and evaluate processes using a wide range of continuous, digital and autonomous manufacturing technologies enabling flexible and adaptable manufacturing solutions.
This enables you to create a bespoke process that is perfectly tailored to molecule and market needs, be it just-in-time or real-time-release manufacturing. We offer:
- Advanced process controls through digital design and integrated process analytics
- Reduced capital outlays and overall inventory costs
- Greater production efficiency
Enabling smart & continuous pharmaceutical processing
We partner with our customers to innovate pharmaceutical processing. We have developed significant capability in smart continuous wet-granulation technology including an integrated combination of process analytical technology (PAT) and statistical quality by design (QbD) methods to develop autonomous process control systems.
Linked with a digital twin, this enables rapid future process development through predictive digital design, based on real experimental data, for accurate modelling and increased development speed at reduced cost.
Nanomedicines and API Formulation
At CPI, we provide solutions to meet the evolving needs of the pharmaceutical industry.
Several novel and cutting-edge techniques, such as active encapsulation and nanoformulation, enable active drug particle delivery in a controlled time-and location-specific manner.
Our scientific expertise and nanomedicine development services integrate microfluidic and analytical technologies to provide formulation solutions to tackle clinical efficacy issues associated with right-time, right-place delivery, such as active delivery through the blood-brain barrier for neurological indications or orally-delivered proteins.
We also offer a variety of formulation services designed to improve efficacy and rapidly progress development. Services include API formulation feasibility studies and powder formulation characterisation. With established success across multiple sectors, such as FMCG and consumer care, we translate this experience to cross-sectoral formulation challenges and utilise high throughput robotics for rapid formulation screening and development.
The Medicines Manufacturing Innovation Centre
This unique state-of-the-art GMP facility offers transformative, digital-enabled solutions in pharmaceutical manufacturing. It enableses industry, academia, healthcare providers
and regulators to work collaboratively to address challenges and maximise technology opportunities within the medicines supply chain.
The centre is a collaboration between CPI, University of Strathclyde, UK Research & Innovation, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.
Let’s innovate together
To find out more about how we can work together, please enter your details below.